150 related articles for article (PubMed ID: 38033274)
21. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A
J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885
[TBL] [Abstract][Full Text] [Related]
22. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.
Kerr KM; Bubendorf L; Edelman MJ; Marchetti A; Mok T; Novello S; O'Byrne K; Stahel R; Peters S; Felip E;
Ann Oncol; 2014 Sep; 25(9):1681-1690. PubMed ID: 24718890
[TBL] [Abstract][Full Text] [Related]
23. Promises and challenges in developing miRNA as a molecular diagnostic tool for lung cancer.
Cho WC
Expert Rev Mol Diagn; 2011 Nov; 11(8):763-6. PubMed ID: 22022936
[No Abstract] [Full Text] [Related]
24. Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer.
Delgado-García M; Weynand B; Gómez-Izquierdo L; Hernández MJ; Blanco ÁM; Varela M; Matias-Guiu X; Nadal E; Márquez-Lobo B; Alarcão A; de Álava E; Biscuola M
BMC Cancer; 2020 Apr; 20(1):275. PubMed ID: 32245434
[TBL] [Abstract][Full Text] [Related]
25. Biomarker testing in non-small cell lung cancer: a clinician's perspective.
Bernicker E
Arch Pathol Lab Med; 2015 Apr; 139(4):448-50. PubMed ID: 25166873
[No Abstract] [Full Text] [Related]
26. Molecular Testing for Targeted Therapy in Advanced Non-Small Cell Lung Cancer: Suitability of Endobronchial Ultrasound Transbronchial Needle Aspiration.
Casadio C; Guarize J; Donghi S; Di Tonno C; Fumagalli C; Vacirca D; Dell'Orto P; De Marinis F; Spaggiari L; Viale G; Barberis M
Am J Clin Pathol; 2015 Oct; 144(4):629-34. PubMed ID: 26386084
[TBL] [Abstract][Full Text] [Related]
27. Genetic testing for lung cancer: reflex versus clinical selection.
Bunn PA; Doebele RC
J Clin Oncol; 2011 May; 29(15):1943-5. PubMed ID: 21483017
[No Abstract] [Full Text] [Related]
28. Overview and update on molecular testing in non-small cell lung carcinoma utilizing endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) samples.
Fernández Aceñero MJ; Díaz Del Arco C; Dinarés C; Labiano T; Tejerina E; Bernabé MJ; Forcen E; Saiz-Pardo M; Pérez P; Lozano MD
Diagn Cytopathol; 2023 Jan; 51(1):26-35. PubMed ID: 35899869
[TBL] [Abstract][Full Text] [Related]
29. Prevalence and breakdown of EGFR exon 20 driver mutations in routine NHS lung cancer diagnostic testing.
Moore DA; Balbi KJ; Poskitt B; Bennett P
J Clin Pathol; 2022 Mar; 75(3):209-210. PubMed ID: 34168072
[No Abstract] [Full Text] [Related]
30. [Significance of molecular technology in diagnosis and therapy of non-small-cell lung cancer].
Chen XX; Zhou CC
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):570-2. PubMed ID: 23157756
[No Abstract] [Full Text] [Related]
31. The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer.
Ross K; Pailler E; Faugeroux V; Taylor M; Oulhen M; Auger N; Planchard D; Soria JC; Lindsay CR; Besse B; Vielh P; Farace F
Expert Rev Mol Diagn; 2015; 15(12):1605-29. PubMed ID: 26564313
[TBL] [Abstract][Full Text] [Related]
32. [Pretreatment molecular biology analysis on small size biopsies].
Antoine M; Poulot V; Colombat M; Fleury J; Lacave R; Cadranel J
Ann Pathol; 2010 Nov; 30(5 Suppl 1):67-72. PubMed ID: 21055550
[No Abstract] [Full Text] [Related]
33. [Lung cancer: progress in diagnosis and treatments. Topics: IV. Recent topics; 1. Driver mutations in non-small cell lung cancer].
Mano H
Nihon Naika Gakkai Zasshi; 2014 Jun; 103(6):1355-9. PubMed ID: 25151801
[No Abstract] [Full Text] [Related]
34. A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms.
Beau-Faller M; Blons H; Domerg C; Gajda D; Richard N; Escande F; Solassol J; Denis MG; Cayre A; Nanni-Metellus I; Olschwang S; Lizard S; Piard F; Pretet JL; de Fraipont F; Bièche I; de Cremoux P; Rouquette I; Bringuier PP; Mosser J; Legrain M; Voegeli AC; Saulnier P; Morin F; Pignon JP; Zalcman G; Cadranel J
J Mol Diagn; 2014 Jan; 16(1):45-55. PubMed ID: 24183959
[TBL] [Abstract][Full Text] [Related]
35.
Socinski MA; Pennell NA; Davies KD
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036238
[No Abstract] [Full Text] [Related]
36. [Mutation testing for non-small-cell lung cancer].
Brustugun OT; Helland Å; Fjellbirkeland L; Kleinberg L; Ariansen S; Jebsen P; Scott H; Dønnem T; Bremnes R; Berg T; Grønberg BH; Dai HY; Wahl SG; Mangseth K; Helgeland L
Tidsskr Nor Laegeforen; 2012 Apr; 132(8):952-5. PubMed ID: 22562326
[TBL] [Abstract][Full Text] [Related]
37. [Histologic subtyping of poorly-differentiated solid lung cancer with molecular testing for epidermal growth factor receptor mutation and ALK gene rearrangement: an analyses of 167 cases].
Fang F; Wang YX; Hu ST; Yang L; Di J; Liu DG; Lyu N
Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):432-437. PubMed ID: 29886587
[No Abstract] [Full Text] [Related]
38. Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch Population.
Sluga R; VAN DEN Borne BEEM; Roepman P; Peters BJM; Kastelijn EA; Schramel FMNH
Anticancer Res; 2018 Jan; 38(1):393-400. PubMed ID: 29277800
[TBL] [Abstract][Full Text] [Related]
39. [Mutation of the BRAF genes in non-small cell lung cancer].
Huang Z; Wu Y
Zhongguo Fei Ai Za Zhi; 2012 Mar; 15(3):183-6. PubMed ID: 22429583
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor in lung cancer: the amazing interplay of molecular testing and cytopathology.
Idowu MO
Cancer Cytopathol; 2013 Oct; 121(10):540-3. PubMed ID: 23780849
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
